Overcoming resistance to immunotherapy
Developing a screening technique to provide clinicians with rationale for selecting a drug treatment regime.
Developing a screening technique to provide clinicians with rationale for selecting a drug treatment regime.
Understanding the genes involved in the development of early brain metastases.
Identifying genes involved in all melanoma sub-types, to determine the most effective treatment.
Using whole genome sequencing technologies to identify the genetic mutations that cause melanoma, so treatment can be personalised.
Identifying genes which determine response to immunotherapy, and then determining the signalling pathways these genes are affecting.
MIA is experiencing great success with multi-discipline trials in the neo-adjuvant and adjuvant settings.
Research to determine the value of providing patients with the services of a support clinic following dissection surgery.
An observational study to determine best practice based on clinicians’ reported management of NSW melanoma patients over a 12-month period.
Searching for early-detection genetic markers and treatment options for 20 to 39 year olds.
Investigating including electronic Patient Reported Outcome Measures into routine care for Stage III melanoma patients.